This year was defined by innovation, global reach, strategic leadership changes, and a stronger commitment than ever to our core mission: enabling early, safe, and efficient detection of eye diseases through advanced, user-friendly technology. Let’s revisit some of the key milestones that made 2024 such a transformative year for RetinaLyze.
A New Version of the RetinaLyze Software:
In 2024, we launched the next generation of our fundus analysis platform - an upgrade that seamlessly integrates enhanced AI capabilities, a more intuitive user interface, and streamlined functionalities. The result? A more efficient workflow and an even better experience for eye care professionals. From improved patient history reviews and faster AI analyses to more space-efficient layouts and effortless consultation sorting, we’ve focused on features that help specialists focus on what matters most: their patients.
Introducing Teddy Birch Petersen:
We were delighted to announce Teddy Birch Petersen as our new CEO. Teddy’s deep understanding of the healthcare tech landscape, along with a proven track record of operational excellence and an entrepreneurial spirit, makes him the perfect leader for our next phase. Under Teddy’s guidance, RetinaLyze will continue pushing boundaries in early disease detection, ensuring our solutions are as accessible, accurate, and impactful as possible.
Featured by the College of Optometrists:
We were honored to be part of the conversation in the College of Optometrists’ recent publication, “Is early diagnosis always better?” The article underscored the power of oculomics and AI-driven tools. Insights from Prof. Alastair Denniston highlighted the huge potential in leveraging the eye as a window to overall health. Our own Chris Flynn, UK Lead at RetinaLyze, emphasized our aim: to be the “optometrist’s best friend,” offering decision support that identifies early disease signals before they’re visible to the human eye alone.
Seeking New Distributors:
To serve more markets and communities, we actively sought new distribution partners. If your company has the expertise and market know-how to bring cutting-edge AI eye-screening to healthcare professionals, we’d love to hear from you.
Brazilian Market Entry:
This was the year RetinaLyze made its debut in Brazil, partnering with Avita/NCS Healthcare. This move enables Brazilian healthcare professionals and patients to access advanced AI tools for better eye health outcomes. We look forward to growing in this vibrant, dynamic market.
Partnership with Medicontur CZ:
In the Czech Republic, a new alliance with Medicontur CZ brought our innovation closer to ophthalmology professionals and patients. Working together, we aim to enhance early detection of diseases like diabetic retinopathy, AMD, and glaucoma, ultimately elevating eye health standards in the region.
Partnership with Surveye:
In Slovakia, a new alliance with Surveye begins our journey in the Slovak ophthalmology market. We're excited to see where we can go together in 2025!
Introducing RetinaLyze Advanced Glaucoma:
Glaucoma can be notoriously difficult to detect due to its slow progression. Our new Glaucoma Individual Pointer (GIP) tool changes the game. By analyzing data from multiple consultations, GIP pinpoints subtle changes over time, enabling earlier, more accurate diagnosis. Leading eye care publications—from EyeWirePlus to Glaucoma Today—have taken note, highlighting the importance of this breakthrough.
Highlighted by HealthSolutionsDK.com:
RetinaLyze was showcased on HealthSolutionsDK.com, reflecting our commitment to innovating in eye health tech. With support from The Trade Council of Denmark in Latin America and partners like the Danish Life Science Cluster and the Danish Export Association, this feature spotlights our dedication to preventing blindness through advanced screening.
Redesigned PDF Reports:
We understand that clarity and customization are crucial. That’s why we revamped our reporting process. All images, scans, and analyses are now compiled into a single PDF report. Plus, users can edit AI-generated results, ensuring that each report perfectly meets their needs.
Every 36 Seconds:
Since December 2013, our AI-aided screenings have worked tirelessly, performing a screening every 36 seconds. This relentless activity underscores the global impact RetinaLyze is having on early disease detection and prevention.
Broad Device Compatibility:
Over the years, we’ve ensured that RetinaLyze integrates smoothly with more than 60 different devices—from giants like Canon, Essilor, NIDEK, Topcon, ZEISS, and more—making it easy for professionals to incorporate our tools into their existing workflows.
2024 has been a year of significant achievements and meaningful contributions. We’ve refined our technology, expanded our global reach, broadened our partnerships, and received recognition from both our peers and the wider healthcare community. Most importantly, we’ve continued working towards our mission: improving patient outcomes through early detection and efficient eye screening.
As we move into 2025, we remain committed to innovation, collaboration, and the pursuit of better vision health for everyone. We thank our partners, our users, and everyone who believes in the power of advancing eye care through technology.
Here’s to another year of seeing what’s possible—together.
